These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
461 related articles for article (PubMed ID: 34649219)
1. Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment. Liang C; Li J; Tian B; Tian L; Liu Y; Li J; Xin L; Wang J; Fu C; Shi Z; Xia J; Liang Y; Wang K Biomed Pharmacother; 2021 Dec; 144():112298. PubMed ID: 34649219 [TBL] [Abstract][Full Text] [Related]
2. Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition. Nguyen G; Park SY; Le CT; Park WS; Choi DH; Cho EH Biochem Biophys Res Commun; 2018 Jan; 495(4):2649-2656. PubMed ID: 29278707 [TBL] [Abstract][Full Text] [Related]
3. Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease. Kimura T; Singh S; Tanaka N; Umemura T Front Endocrinol (Lausanne); 2021; 12():773432. PubMed ID: 34938271 [TBL] [Abstract][Full Text] [Related]
4. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228 [TBL] [Abstract][Full Text] [Related]
5. Succinate causes α-SMA production through GPR91 activation in hepatic stellate cells. Li YH; Woo SH; Choi DH; Cho EH Biochem Biophys Res Commun; 2015 Aug; 463(4):853-8. PubMed ID: 26051274 [TBL] [Abstract][Full Text] [Related]
6. Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis. Wree A; Mehal WZ; Feldstein AE Semin Liver Dis; 2016 Feb; 36(1):27-36. PubMed ID: 26870930 [TBL] [Abstract][Full Text] [Related]
7. Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease. Xu JY; Li ZP; Zhang L; Ji G World J Gastroenterol; 2014 Oct; 20(37):13493-500. PubMed ID: 25309079 [TBL] [Abstract][Full Text] [Related]
9. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH. Oniciu DC; Hashiguchi T; Shibazaki Y; Bisgaier CL PLoS One; 2018; 13(5):e0194568. PubMed ID: 29847555 [TBL] [Abstract][Full Text] [Related]
10. HWL-088, a new and highly effective FFA1/PPARδ dual agonist, attenuates nonalcoholic steatohepatitis by regulating lipid metabolism, inflammation and fibrosis. Hu L; Zhou Z; Deng L; Ren Q; Cai Z; Wang B; Li Z; Wang G J Pharm Pharmacol; 2020 Nov; 72(11):1564-1573. PubMed ID: 32734608 [TBL] [Abstract][Full Text] [Related]
11. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease. Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399 [TBL] [Abstract][Full Text] [Related]
12. Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). Grattagliano I; Di Ciaula A; Baj J; Molina-Molina E; Shanmugam H; Garruti G; Wang DQ; Portincasa P Methods Mol Biol; 2021; 2310():201-246. PubMed ID: 34096005 [TBL] [Abstract][Full Text] [Related]
13. Sirtuin 3 (SIRT3) Regulates α-Smooth Muscle Actin (α-SMA) Production through the Succinate Dehydrogenase-G Protein-coupled Receptor 91 (GPR91) Pathway in Hepatic Stellate Cells. Li YH; Choi DH; Lee EH; Seo SR; Lee S; Cho EH J Biol Chem; 2016 May; 291(19):10277-92. PubMed ID: 26912655 [TBL] [Abstract][Full Text] [Related]
14. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Chow MD; Lee YH; Guo GL Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273 [TBL] [Abstract][Full Text] [Related]
15. Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. Lambrecht J; van Grunsven LA; Tacke F Expert Opin Pharmacother; 2020 Sep; 21(13):1637-1650. PubMed ID: 32543284 [TBL] [Abstract][Full Text] [Related]
16. INT-767 improves histopathological features in a diet-induced Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205 [TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH). Lee JH; Oh JY; Kim SH; Oh IJ; Lee YH; Lee KW; Lee WH; Kim JH Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33050067 [TBL] [Abstract][Full Text] [Related]
18. Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice. Du M; Wang X; Yuan L; Liu B; Mao X; Huang D; Yang L; Huang K; Zhang F; Wang Y; Luo X; Wang C; Peng J; Liang M; Huang D; Huang K J Hepatol; 2020 Dec; 73(6):1333-1346. PubMed ID: 32717288 [TBL] [Abstract][Full Text] [Related]
19. Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and therapeutic advances. Cruz-Ramón V; Chinchilla-López P; Ramírez-Pérez O; Méndez-Sánchez N Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s58-s67. PubMed ID: 29080343 [TBL] [Abstract][Full Text] [Related]
20. Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementation. Liu XJ; Xie L; Du K; Liu C; Zhang NP; Gu CJ; Wang Y; Abdelmalek MF; Dong WY; Liu XP; Niu C; Yang C; Diehl AM; Wu J Liver Int; 2020 Apr; 40(4):830-843. PubMed ID: 31903720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]